Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521Phase 3Recruiting
- Sponsor
- UCB
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Started May 2026; status: recruiting.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07463521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07463521.